#China #Beijing #Keymed Biosciences #Kangyueda #CMG901

Keymed Biosciences Reports Significant Growth in 2025

Keymed Biosciences, a prominent player in the biotechnology sector, recently revealed its financial performance for the fiscal year 2025, marking a substantial achievement. The company announced that its total revenue for the year amounted to approximately 720 million RMB, reflecting a remarkable 67% increase compared to the previous year. This impressive growth is largely attributed to the robust sales of its core product, Kangyueda®, which generated around 310 million RMB, alongside significant collaboration revenues totaling about 410 million RMB.

One of the key highlights from this announcement was the company's commitment to continuous innovation through sustained investment in research and development. Keymed maintained its R&D expenditure at around 720 million RMB, emphasizing its dedication to advancing medical science and developing groundbreaking therapies.

As of December 31, 2025, Keymed reported cash reserves reaching approximately 1.96 billion RMB, providing a solid financial foundation for ongoing operations and future initiatives. This strong liquidity position positions the company to pursue new opportunities and support its current and upcoming projects effectively.

In a significant regulatory milestone, the National Medical Products Administration (NMPA) of China granted approval for new indications for Kangyueda® targeting moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. As of January 2026, all approved indications were included in the National Reimbursement Drug List of China, enhancing affordability and accessibility for patients across the nation, a major step forward for healthcare in China. During the reporting period, sales from Kangyueda® reached around 315 million RMB, indicating strong market demand and brand acceptance.

Additionally, Keymed disclosed advancements regarding its promising therapeutic candidate CMG901 (AZD0901), a first-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2. The drug has been licensed out to AstraZeneca for global development, with multiple Phase III clinical trials progressing swiftly. In a notable development in February 2026, the first subject received a dose in this clinical study, resulting in a milestone payment of 45 million USD to Keymed Biosciences.

Furthermore, another compound, CM336 (a bispecific antibody targeting BCMA x CD3), has been licensed to Ouro Medicines for worldwide development outside of Greater China. Recently, Ouro Medicines announced a merger with Gilead Sciences, which entails a substantial upfront payment of 1,675 million USD, subject to customary adjustments, along with contingent milestone payments totaling up to 500 million USD, bringing the potential total consideration to about 2.175 billion USD. Keymed anticipates receiving an initial payment of approximately 250 million USD and contingent milestone payments of up to 70 million USD based on its stake in Ouro Medicines.

Keymed Biosciences is leveraging multiple technology platforms to drive its innovative drug development pipeline, including antibody discovery platforms, ADC platforms, and antibody delivery systems capable of traversing the blood-brain barrier, among others. The integration of these synergistic innovation platforms is aimed at continuously creating high-quality, innovative medicines that meet patient needs globally.

In conclusion, Keymed Biosciences has positioned itself as a dynamic enterprise within the biotech landscape, showcasing robust financial growth in 2025 while expanding its product offerings through strategic partnerships and regulatory approvals. As the company continues to push forward in its mission to enhance healthcare outcomes, it remains focused on innovation and collaboration to drive its future success.

For further information regarding Keymed Biosciences and its latest initiatives, please visit Keymed Biosciences.